Form 4: Haemonetics CAO Reports RSU Vesting and Grant

Haemonetics Corporation Chief Accounting Officer Maryanne Maunsell Farris reported the vesting of restricted stock units and a new equity grant.

Summary

• Maryanne Maunsell Farris, VP and Chief Accounting Officer, executed transactions involving Haemonetics Corporation (HAE) common stock on May 15, 2026.
• 197 shares were withheld to satisfy tax obligations related to the vesting of previously reported restricted stock units (RSUs).
• A new grant of 2,220 RSUs was awarded under the 2019 Long-Term Incentive Compensation Plan.
• Following these transactions, the reporting person holds a total of 6,501 shares, including unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine executive compensation activity rather than a change in company strategy or financial performance.

Positives

• The transaction reflects standard equity compensation practices for executive retention.
• The reporting person maintains a significant beneficial ownership position of 6,501 shares.

Negatives

• None identified; this is a routine regulatory disclosure of executive compensation.

Risks

• None identified; this filing pertains to internal equity compensation rather than operational or market risks.

Future Outlook

The newly granted RSUs are scheduled to vest in three equal annual installments, beginning on the first anniversary of the grant date.

Management Comments

• The transactions were executed pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.

Industry Context

StockSavvy.ai notes that this filing is a standard administrative disclosure common in the medical device and healthcare technology sector, where equity-based compensation is a primary tool for executive alignment.

Comparison to Industry Standards

• The use of RSUs as a long-term incentive is consistent with standard corporate governance practices for S&P 400/500 companies.
• Tax withholding upon vesting is a standard industry procedure for managing executive equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as these are standard equity compensation adjustments.

Next Steps

• The reporting person will continue to hold the granted RSUs subject to the three-year vesting schedule.

Key Dates

Keywords

Haemonetics, HAE, Form 4, Insider Trading, Equity Compensation, Chief Accounting Officer